Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women.

Roberts L, Passmore JA, Mlisana K, Williamson C, Little F, Bebell LM, Walzl G, Abrahams MR, Woodman Z, Abdool Karim Q, Abdool Karim SS.

J Infect Dis. 2012 Jan 15;205(2):194-203. doi: 10.1093/infdis/jir715.

3.

Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding.

Jaspan HB, Liebenberg L, Hanekom W, Burgers W, Coetzee D, Williamson AL, Little F, Myer L, Coombs RW, Sodora D, Passmore JA.

J Infect Dis. 2011 Nov 15;204(10):1550-6. doi: 10.1093/infdis/jir591. Epub 2011 Sep 21.

4.

Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused?

Marrazzo JM.

Anaerobe. 2011 Aug;17(4):186-90. doi: 10.1016/j.anaerobe.2011.03.016. Epub 2011 Apr 16. Review.

5.

Molecular methods to describe the spectrum and dynamics of the vaginal microbiota.

Fredricks DN.

Anaerobe. 2011 Aug;17(4):191-5. doi: 10.1016/j.anaerobe.2011.01.001. Epub 2011 Mar 3.

6.

The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth.

Graver MA, Wade JJ.

Ann Clin Microbiol Antimicrob. 2011 Feb 17;10:8. doi: 10.1186/1476-0711-10-8.

7.

A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.

Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC.

PLoS One. 2011 Jan 25;6(1):e16475. doi: 10.1371/journal.pone.0016475.

8.

Sexually transmitted diseases treatment guidelines, 2010.

Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 Dec 17;59(RR-12):1-110. Erratum in: MMWR Recomm Rep. 2011 Jan 14;60(1):18. Dosage error in article text.

9.

Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium.

Hwang LY, Scott ME, Ma Y, Moscicki AB.

J Reprod Immunol. 2011 Jan;88(1):66-71. doi: 10.1016/j.jri.2010.07.008. Epub 2010 Nov 3.

10.

Protective immunity to chlamydial genital infection: evidence from animal studies.

Rank RG, Whittum-Hudson JA.

J Infect Dis. 2010 Jun 15;201 Suppl 2:S168-77. doi: 10.1086/652399. Review.

PMID:
20470052
11.

Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception.

Shust GF, Cho S, Kim M, Madan RP, Guzman EM, Pollack M, Epstein J, Cohen HW, Keller MJ, Herold BC.

Am J Reprod Immunol. 2010 Feb;63(2):110-9. doi: 10.1111/j.1600-0897.2009.00768.x. Epub 2009 Dec 15. Erratum in: Am J Reprod Immunol.2010 May 1;63(5):410. Dosage error in article text.

12.

Repeated Chlamydia trachomatis genital infections in adolescent women.

Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard DR, Orr DP, Katz BP, Fortenberry JD.

J Infect Dis. 2010 Jan 1;201(1):42-51. doi: 10.1086/648734.

13.

In vitro inhibitory activity of human vaginal lactobacilli against pathogenic bacteria associated with bacterial vaginosis in Kenyan women.

Matu MN, Orinda GO, Njagi EN, Cohen CR, Bukusi EA.

Anaerobe. 2010 Jun;16(3):210-5. doi: 10.1016/j.anaerobe.2009.11.002. Epub 2009 Nov 20.

PMID:
19925874
14.

Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread.

Välimaa H, Tenovuo J, Waris M, Hukkanen V.

Virol J. 2009 May 12;6:53. doi: 10.1186/1743-422X-6-53.

15.

Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR.

Fredricks DN, Fiedler TL, Thomas KK, Mitchell CM, Marrazzo JM.

J Clin Microbiol. 2009 Mar;47(3):721-6. doi: 10.1128/JCM.01384-08. Epub 2009 Jan 14. Erratum in: J Clin Microbiol. 2014 Aug;52(8):3137.

16.

Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition.

Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, Broliden K, Hirbod T; Kibera HIV Study Group.

AIDS. 2009 Jan 28;23(3):309-17. doi: 10.1097/QAD.0b013e328321809c.

PMID:
19114868
17.

Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment.

Rebbapragada A, Howe K, Wachihi C, Pettengell C, Sunderji S, Huibner S, Ball TB, Plummer FA, Jaoko W, Kaul R.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):520-2. doi: 10.1097/QAI.0b013e318189a7ca.

PMID:
18989228
18.

Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies.

Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS.

AIDS. 2008 Jul 31;22(12):1493-501. doi: 10.1097/QAD.0b013e3283021a37. Review.

19.

Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.

Marrazzo JM, Thomas KK, Fiedler TL, Ringwood K, Fredricks DN.

Ann Intern Med. 2008 Jul 1;149(1):20-8.

20.

Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid.

Khot PD, Ko DL, Hackman RC, Fredricks DN.

BMC Infect Dis. 2008 May 29;8:73. doi: 10.1186/1471-2334-8-73.

Supplemental Content

Support Center